Cargando…
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants
PURPOSE: Galectin-3, a β-galactoside-binding lectin, plays a key role in several cellular pathways involved in chronic inflammation, heart disease and cancer. GB1211 is an orally bioavailable galectin-3 inhibitor, developed to be systemically active. We report safety and pharmacokinetics (PK) of GB1...
Autores principales: | Aslanis, Vassilios, Slack, Robert J., MacKinnon, Alison C., McClinton, Catherine, Tantawi, Susan, Gravelle, Lise, Nilsson, Ulf J., Leffler, Hakon, Brooks, Ashley, Khindri, Sanjeev K., Marshall, Richard P., Pedersen, Anders, Schambye, Hans, Zetterberg, Fredrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010643/ https://www.ncbi.nlm.nih.gov/pubmed/36914828 http://dx.doi.org/10.1007/s00280-023-04513-y |
Ejemplares similares
-
Discovery and
Optimization of the First Highly Effective
and Orally Available Galectin-3 Inhibitors for Treatment of
Fibrotic Disease
por: Zetterberg, Fredrik R., et al.
Publicado: (2022) -
Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
por: Mabbitt, Joseph, et al.
Publicado: (2023) -
Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation
por: Humphries, Duncan C., et al.
Publicado: (2022) -
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis
por: Hirani, Nikhil, et al.
Publicado: (2021) -
Extracellular and intracellular small-molecule galectin-3 inhibitors
por: Stegmayr, John, et al.
Publicado: (2019)